Acrivon Therapeutics, Inc. (ACRV)
1.75
+0.03
(+1.74%)
USD |
NASDAQ |
Oct 15, 15:55
Acrivon Therapeutics EPS Diluted (Quarterly) : -0.4293 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4293 |
| March 31, 2026 | -0.4917 |
| December 31, 2025 | -0.4911 |
| September 30, 2025 | -0.4729 |
| June 30, 2025 | -0.5462 |
| March 31, 2025 | -0.5132 |
| December 31, 2024 | -0.597 |
| September 30, 2024 | -0.5889 |
| June 30, 2024 | -0.5202 |
| March 31, 2024 | -0.7298 |
| Date | Value |
|---|---|
| December 31, 2023 | -0.862 |
| September 30, 2023 | -0.6551 |
| June 30, 2023 | -0.6333 |
| March 31, 2023 | -0.5819 |
| December 31, 2022 | -0.4275 |
| September 30, 2022 | -0.4404 |
| June 30, 2022 | -0.279 |
| March 31, 2022 | -0.3457 |
| December 31, 2021 | -0.2089 |
| September 30, 2021 | -0.1168 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.96M |
| Total Expenses (Quarterly) | 17.96M |
| Enterprise Value | -14.15M |
| Earnings Yield | -107.7% |
| Normalized Earnings Yield | -107.71 |